OTCM
HMTXF
Market cap9mUSD
Oct 02, Last price
0.04USD
Name
Hemostemix Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
38.35%
Rev. gr., 5y
%
Revenues
0
Net income
-5m
L+80.20%
CFO
-5m
L+138.41%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Key people
Independent Chairman of the Board · since 2020
Thomas Smeenk
President, Chief Executive Officer, Director · since 2020
Christina Wu
Interim Chief Financial Officer · since 2020
Sana Farooqui
Chief Marketing Officer · since 2025
Croom Lawrence
Chief Commercialization Officer · since 2025
Ronnie Hershman
Independent Director · since 2020
Loran Swanberg
Independent Director · since 2020
Headquarters & legal address
707 7 AVENUE
SUITE 1150
CALGARY, AB T2P 3H6
CA
SUITE 1150
CALGARY, AB T2P 3H6
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||